Last reviewed · How we verify
NgG medium dose investigational vaccine
NgG medium dose investigational vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | NgG medium dose investigational vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NgG medium dose investigational vaccine CI brief — competitive landscape report
- NgG medium dose investigational vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about NgG medium dose investigational vaccine
What is NgG medium dose investigational vaccine?
NgG medium dose investigational vaccine is a Biologic drug developed by GlaxoSmithKline.
Who makes NgG medium dose investigational vaccine?
NgG medium dose investigational vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is NgG medium dose investigational vaccine in?
NgG medium dose investigational vaccine is in Phase 1.